An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease (Q44239114)

From Wikidata

Jump to navigation Jump to search

scientific article published in December 2002

Language	Label	Description	Also known as
English	An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease	scientific article published in December 2002

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

adverse prognostic factor

1 reference

based on heuristic

inferred from title

Fernando Cabanillas

9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Gregory M Chronowski

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Richard B Wilder

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Susan L Tucker

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Chul S Ha

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Andreas H Sarris

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Fredrick B Hagemeister

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Ibrahim Barista

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Mark A Hess

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

James D Cox

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

1 December 2002

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

2534-2538

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic role of serum beta 2-microglobulin in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of tumour burden in Hodgkin's disease PS I and II

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy results in laparotomy-staged Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

The significance of mediastinal involvement in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

The small subunit of HL-A antigens is beta 2-microglobulin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum beta2microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum beta 2-microglobulin in malignant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum beta 2-microglobulin in malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum beta 2 microglobulin in malignant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10998

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10998

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44239114&oldid=2116613970"